Simcere Pharmaceutical (2096 HK): Focus Shifts to Innovative Drug; COVID-19 Oral Drug in Development
Simcere is expected to continue strong performance driven by increasing contribution of innovative drugs. Rich pipeline entails visibility. The...
371 Views
Kazia Therapeutics - Multiple paxalisib data points expected in Q4
Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in...
597 Views
Kazia Therapeutics - Multiple paxalisib data points expected in Q4
Kazia expects to release multiple data points from its paxalisib programme in Q4 CY21. These include final data from the 30-patient Phase II trial...
655 Views
Kazia Therapeutics: Pivotal Phase 3 Study Underway
Kazia Therapeutics Pivotal phase 3 study underway Kazia Therapeutics (ASX:KZA) is an oncology focused drug development company with lead...
1.1k Views
Video: Kazia Therapeutics - overview and update with CEO James Garner
Kazia Therapeutics (KZA) is an oncology-focused drug development company. Its drug candidates are designed to treat diseases which are poorly...
501 Views
No more insights